Minocycline
- Generic Name
- Minocycline
- Brand Names
- Amzeeq, Arestin, Dynacin, Minocin, Minolira, Solodyn, Ximino, Zilxi
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27N3O7
- CAS Number
- 10118-90-8
- Unique Ingredient Identifier
- FYY3R43WGO
- Background
Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.
...
- Indication
Oral and topical minocycline are indicated to treat inflammatory lesions of acne vulgaris. Subgingival microspheres are indicated as an adjunct treatment in the reduction of pocket depth in adults with periodontitis. Oral and intravenous formulations are indicated to treat infections of susceptible microorganisms. These include rickettsiae, Mycoplasma pneumo...
- Associated Conditions
- Bartonellosis, Brucellosis, Campylobacter fetus, Chancroid, Cholera (Disorder), Conjunctivitis, Inclusion, Granuloma Inguinale, Lymphogranuloma Venereum, Nongonococcal urethritis, Periodontitis, Plague, Psittacosis, Q Fever, Relapsing Fever, Respiratory Tract Infections (RTI), Rickettsia Infections, Rickettsialpox, Rocky Mountain Spotted Fever, Trachoma, Tularemia, Typhus infections, Inflammatory lesions
- Associated Therapies
- -
Evaluating the Efficacy of Adjunctive Minocycline for the Treatment of Bipolar Depression
- Conditions
- Interventions
- First Posted Date
- 2011-07-27
- Last Posted Date
- 2016-12-19
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 29
- Registration Number
- NCT01403662
- Locations
- 🇨🇦
University Health Network, Toronto, Ontario, Canada
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
- First Posted Date
- 2011-05-06
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 47
- Registration Number
- NCT01349192
- Locations
- 🇺🇸
St. Louis Children's Hospital, St. Louis, Missouri, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸The Children's Hospital, Aurora, Colorado, United States
Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo in Patients With Schizophrenia or Schizoaffective Disorder
- Conditions
- Interventions
- First Posted Date
- 2011-03-23
- Last Posted Date
- 2011-03-23
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 400
- Registration Number
- NCT01320982
- Locations
- 🇷🇴
Clinica de Psihiatrie, Arad, Romania
🇷🇴Spitalul Clinic de Psihiatrie "Prof. Dr. Alex. Obregia", Bucuresti, Romania
🇷🇴Sp. Jud. "Prof. Dr.O. Fodor", Cluj-Napoca, Romania
A Study for Reducing Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer by Minocycline and Armodafinil
- Conditions
- Interventions
- First Posted Date
- 2011-03-17
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 14
- Registration Number
- NCT01317550
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Minocycline for the Prevention of Post-operative Intercostal Neuralgia
- First Posted Date
- 2011-03-14
- Last Posted Date
- 2013-02-06
- Lead Sponsor
- University of Adelaide
- Target Recruit Count
- 116
- Registration Number
- NCT01314482
- Locations
- 🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
Evaluation of Neuroprotective Effect of Minocycline
- First Posted Date
- 2011-02-17
- Last Posted Date
- 2011-02-17
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Registration Number
- NCT01297816
- Locations
- 🇮🇷
Labbafinejad medical center, Tehran, Iran, Islamic Republic of
Prevention of Treatment Induced Neuropathy in Multiple Myeloma
- First Posted Date
- 2011-01-26
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 79
- Registration Number
- NCT01283997
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Symptom Burden in Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-10-13
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT01219673
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study.
- First Posted Date
- 2010-08-02
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 47
- Registration Number
- NCT01173692
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]
- Conditions
- Interventions
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2013-12-27
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 305
- Registration Number
- NCT01134627
- Locations
- 🇩🇰
Scleroseklinikken afsnit 2082, Copenhagen, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.